CBG
Cannabigerol · CBG · Discovered 1964
Discover CBG (Cannabigerol), the 'mother of all cannabinoids' and precursor to THC, CBD, and CBC. Explore its unique therapeutic potential, mechanism of action, and emerging research.
Psychoactive
No
Discovered
1964
Effects
8 documented
Benefits
4 studied
Overview
Cannabigerol (CBG) is often referred to as the 'mother of all cannabinoids' because its acidic precursor, cannabigerolic acid (CBGA), is the chemical parent from which all other cannabinoids are synthesized within the cannabis plant. Enzymes in the plant convert CBGA into THCA, CBDA, and CBCA, which then decarboxylate into THC, CBD, and CBC respectively. Because of this conversion process, CBG typically exists in very low concentrations (less than 1%) in mature cannabis plants, as most of the CBGA has been converted to other cannabinoids by harvest time.
Recent advances in cannabis genetics have led to the development of CBG-dominant cultivars that can produce 10-20% CBG by weight. These strains are typically harvested earlier in the flowering cycle, before the enzymatic conversion of CBGA to other cannabinoid acids is complete. This has made CBG more commercially accessible and has fueled a surge in research interest. CBG does not produce psychoactive effects and is increasingly recognized for its unique pharmacological profile.
Preclinical research has identified CBG as a promising therapeutic agent for conditions including inflammatory bowel disease, glaucoma, bacterial infections, and neurodegenerative diseases. Unlike CBD, CBG has notable affinity for both CB1 and CB2 receptors, acting as a partial agonist at both, and it also interacts with alpha-2 adrenergic receptors, serotonin 5-HT1A receptors, and TRPV1 channels. CBG's distinct receptor binding profile suggests it may offer therapeutic benefits different from or complementary to CBD.
Mechanism of Action
CBG interacts with the endocannabinoid system as a partial agonist at both CB1 and CB2 receptors, though with lower affinity than THC. Its partial agonism at CB1 receptors is not sufficient to produce psychoactive effects but may contribute to analgesic and neuroprotective activity. CBG also acts as an antagonist at the 5-HT1A serotonin receptor, which may contribute to its anti-nausea effects and differentiate it from CBD (which is a 5-HT1A agonist). It activates alpha-2 adrenergic receptors, potentially contributing to blood pressure regulation and sedative effects at higher doses. CBG is a potent TRPM8 antagonist (relevant to pain and prostate cancer research) and activates TRPV1, TRPV2, TRPA1, and TRPV4 channels involved in pain modulation. Notably, CBG is a potent inhibitor of the FAAH enzyme, increasing endogenous anandamide levels, which may underlie many of its therapeutic effects.
Therapeutic Effects
Potential Benefits
Inflammatory Bowel Disease
Preclinical evidence. A 2013 study in Biochemical Pharmacology found that CBG reduced inflammation in a murine model of colitis, reducing nitric oxide production, oxidative stress markers, and inflammatory cytokines. Human clinical trials are needed.
Glaucoma
Preclinical evidence. CBG has been shown to reduce intraocular pressure in animal models, potentially through its activity at CB1 receptors in the eye. CBG may be more effective than THC for this purpose without psychoactive side effects.
Bacterial Infections (MRSA)
Laboratory evidence. A 2020 study published in ACS Infectious Diseases found that CBG was remarkably effective against methicillin-resistant Staphylococcus aureus (MRSA), performing comparably to vancomycin in a murine systemic infection model.
Huntington's Disease
Preclinical evidence. A 2015 study in Neurotherapeutics showed that CBG was neuroprotective in a mouse model of Huntington's disease, improving motor deficits and preserving striatal neurons against neurotoxicity.
Side Effects & Risks
- ⚠Generally well-tolerated with few reported side effects
- ⚠Possible drowsiness at higher doses
- ⚠Dry mouth
- ⚠Increased appetite
- ⚠Potential drug interactions via cytochrome P450 enzyme inhibition
- ⚠Limited long-term safety data available
Concentration & Sources
Typical Concentration
Less than 1% in most mature cannabis plants; 10-20% in CBG-dominant hemp cultivars; 300-1500mg per bottle in CBG oils
Found In
CBG-dominant hemp strains (White CBG, Jack Frost CBG, John Snow CBG), young cannabis plants before CBGA conversion, and specialized CBG products including oils, tinctures, and isolates.
Legal Status
Legal in the United States when derived from hemp containing less than 0.3% THC. Not specifically scheduled at the federal level. Legal in most countries as it is non-psychoactive and found in hemp.
Research Summary
CBG research is in its early but rapidly expanding phase. The cannabinoid's role as the biosynthetic precursor to all other cannabinoids makes it fundamentally important to cannabis science. Key research milestones include the 2013 IBD study demonstrating anti-inflammatory effects in colitis models, the 2015 Huntington's disease neuroprotection study, and the 2020 breakthrough showing CBG's remarkable antibacterial activity against MRSA. Current research is exploring CBG for bladder dysfunction, colorectal cancer (where it showed tumor growth inhibition in vivo), appetite stimulation as a non-psychoactive alternative to THC, and neuroinflammatory conditions. The development of CBG-rich cultivars has significantly increased the availability of this cannabinoid for both research and consumer markets, and several clinical trials are in planning or early stages.
Related Cannabinoids
CBG FAQ
What is CBG and why is it called the 'mother cannabinoid'?
CBG (cannabigerol) is called the 'mother of all cannabinoids' because its acidic precursor, CBGA (cannabigerolic acid), is the first cannabinoid produced in the cannabis plant. Specific enzymes then convert CBGA into THCA, CBDA, and CBCA — the precursors to THC, CBD, and CBC respectively. Without CBGA, no other cannabinoids would exist in the plant.
Does CBG get you high?
No, CBG is not psychoactive and does not produce a high. While CBG does interact with CB1 receptors in the brain, its affinity is too low and its mechanism (partial agonism) is insufficient to produce the euphoric effects associated with THC. CBG is considered safe for daytime use without cognitive impairment.
What is CBG good for?
Research suggests CBG may be beneficial for inflammatory bowel disease, glaucoma (by reducing eye pressure), bacterial infections including MRSA, neurodegenerative conditions like Huntington's disease, appetite stimulation, and bladder dysfunction. However, most evidence comes from preclinical (animal and laboratory) studies, and human clinical trials are still limited.
Why is CBG so expensive?
CBG has historically been expensive because it exists in very low concentrations (less than 1%) in mature cannabis plants, requiring large amounts of biomass for extraction. However, the development of CBG-dominant hemp cultivars producing 10-20% CBG has significantly reduced costs. As cultivation of these specialized strains increases, CBG product prices continue to decline and are approaching parity with CBD products.
Can I take CBG and CBD together?
Yes, CBG and CBD can be taken together and may offer complementary benefits. Because they interact with different receptor targets — CBD primarily modulates serotonin 5-HT1A receptors and GABA receptors, while CBG has stronger direct interaction with cannabinoid receptors and alpha-2 adrenergic receptors — the combination may produce broader therapeutic effects. Many products now offer CBG:CBD blends in various ratios.
Continue Exploring
Disclaimer: Cannabinoid information is provided for educational purposes only. Medical benefits are based on published research and are not intended as medical advice. Individual responses to cannabinoids vary. Always consult a healthcare professional before using cannabis for medical purposes. Legal status information is current as of publication but may change — verify your local laws.